A phase I/II study of induction therapy with topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).

被引：0
|
作者：
Nand, S [1 ]
Godwin, J [1 ]
White, C [1 ]
Beltran, O [1 ]
Stiff, P [1 ]
机构：
[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4649
引用
收藏
页码：214B / 214B
页数：1
相关论文
共 50 条
  • [11] Phase I/II study of escalating doses of mitoxantrone in a single injection combined with timed sequential therapy with cytarabine and etoposide in patients with refractory or relapsed acute myeloid leukemia (AML).
    Thomas, X
    Cambier, N
    Taksin, AL
    Reman, O
    Vekhoff, A
    Cordonnier, C
    Leblond, V
    Soler-Michel, P
    Ecstein-Fraïssé, E
    Archimbaud, E
    BLOOD, 1999, 94 (10) : 238B - 238B
  • [12] Pilot trial of Mylotarg, Topotecan and Ara-C in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Alvarez, RH
    Estey, EH
    Kantarjian, HM
    Giles, FJ
    Beran, M
    Thomas, D
    Cortes, JE
    BLOOD, 2002, 100 (11) : 340A - 341A
  • [13] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study.
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Giles, FJ
    Koller, C
    Estey, E
    BLOOD, 1998, 92 (10) : 235A - 235A
  • [14] Combinations of topotecan and liposomal daunorubicin (Daunoxome) in refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Giles, FJ
    Kantarjian, HM
    Cortes, JE
    Koller, C
    Thomas, D
    O'Brien, SM
    Estey, E
    Beran, M
    BLOOD, 1999, 94 (10) : 230B - 230B
  • [15] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study
    Halpern, Anna B.
    Buckley, Sarah A.
    Othus, Megan
    Huebner, Emily M.
    Orlowski, Kaysey F.
    Scott, Bart L.
    Perdue, Andrea M.
    Smith, Heather A.
    Becker, Pamela S.
    Hendrie, Paul C.
    Cassone, Stephanie
    Chen, Tara L.
    Stirewalt, Derek L.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2016, 128 (22)
  • [16] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
  • [17] Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Ravandi, Farhad
    Plunkett, William
    Gandhi, Varsha
    Faderl, Stefan
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Brandt, Mark
    Huang, Xuelin
    Jabbour, Elias
    BLOOD, 2011, 118 (21) : 1550 - 1550
  • [18] A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities
    Chen, Yiming
    Kantarjian, Hagop
    Estrov, Zeev
    Faderl, Stefan
    Ravandi, Farhad
    Rey, Kristy
    Cortes, Jorge
    Borthakur, Gautam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (05): : 341 - 344
  • [19] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    CANCER RESEARCH, 2014, 74 (19)
  • [20] Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis
    Fruehauf, Stefan
    Topaly, Julian
    Buss, Eike C.
    Fischer, Thomas
    Offmann, Oliver G.
    Emmerich, Bertold
    Muller, Martin C.
    Schuld, Peter
    Balleisen, Leopold
    Hehlmann, Rbdiger
    Ho, Anthony D.
    Hochhaus, Andreas
    CANCER, 2007, 109 (08) : 1543 - 1549
12345